Accelerated T2 Mapping for Characterization of Prostate Cancer

Overview

Journal Magn Reson Med

Publisher Wiley

Specialty Radiology

Date 2011 Mar 12

PMID 21394778

Citations 27

Authors

Wei Liu

Baris Turkbey

Julien Senegas

Stefanie Remmele

Sheng Xu

Jochen Kruecker

Marcelino Bernardo

Bradford J Wood

Peter A Pinto

Peter L Choyke

Affiliations

Soon will be listed here.

Abstract

Prostate T(2) mapping was performed in 34 consecutive patients using an accelerated multiecho spin-echo sequence with 4-fold k-space undersampling leading to a net acceleration factor of 3.3 on a 3T scanner. The mean T(2) values from the accelerated and conventional, unaccelerated sequences demonstrated a very high correlation (r = 0.99). Different prostate segments demonstrated similarly good interscan reproducibility (p = not significant) with slightly larger difference at base: 2.0% ± 1.6% for left base and 2.1% ± 1.1% for right base. In patients with subsequent targeted biopsy, T(2) values of histologically proven malignant tumor areas were significantly lower than the suspicious looking but nonmalignant lesions (p < 0.05) and normal areas (p < 0.001): 100 ± 10 ms for malignant tumors, 114 ± 23 ms for suspicious lesions and 149 ± 32 ms for normal tissues. The proposed method can provide an effective approach for accelerated T(2) quantification for prostate patients.

Citing Articles

Retrospectively Quantified T2 Improves Detection of Clinically Significant Peripheral Zone Prostate Cancer.

Sun H, Wang L, Daskivich T, Qiu S, Lee H, Gao C Cancers (Basel). 2025; 17(3).

PMID: 39941750 PMC: 11816083. DOI: 10.3390/cancers17030381.

Feasibility of quantitative relaxometry for prostate target localization and response assessment in magnetic resonance-guided online adaptive stereotactic body radiotherapy.

Subashi E, LoCastro E, Burleson S, Apte A, Zelefsky M, Tyagi N Phys Imaging Radiat Oncol. 2024; 32():100678.

PMID: 39717186 PMC: 11665667. DOI: 10.1016/j.phro.2024.100678.

Cancer detection in patients with prostate-specific antigen levels within the grey zone: can synthetic magnetic resonance imaging aid in the differentiation between prostate cancer and noncancerous lesions?.

Cao W, Lin J, Chen Y, Ling J, Meng T, Wen Z Quant Imaging Med Surg. 2024; 14(12):9157-9168.

PMID: 39698673 PMC: 11651948. DOI: 10.21037/qims-24-1014.

Value of MRI - T2 Mapping to Differentiate Clinically Significant Prostate Cancer.

Bucher A, Egger J, Dietz J, Strecker R, Hilbert T, Frodl E J Imaging Inform Med. 2024; 37(6):3304-3315.

PMID: 38926263 PMC: 11612117. DOI: 10.1007/s10278-024-01150-6.

Magnetic Resonance Image Compilation Was Used in Conjunction with Prostate PI-RADS v2.1 Score Has Diagnostic Relevance for Benign and Malignant Prostate Lesions.

Xu W, Cao H, Du F, He L, Jiang F, Hu C Comput Math Methods Med. 2022; 2022:3613540.

PMID: 36072774 PMC: 9444436. DOI: 10.1155/2022/3613540.

References

de Bazelaire C, Duhamel G, Rofsky N, Alsop D . MR imaging relaxation times of abdominal and pelvic tissues measured in vivo at 3.0 T: preliminary results. Radiology. 2004; 230(3):652-9. DOI: 10.1148/radiol.2303021331. View

Turkbey B, Xu S, Kruecker J, Locklin J, Pang Y, Bernardo M . Documenting the location of prostate biopsies with image fusion. BJU Int. 2010; 107(1):53-7. PMC: 3272674. DOI: 10.1111/j.1464-410X.2010.09483.x. View

Liney G, Lowry M, Turnbull L, Manton D, Knowles A, Blackband S . Proton MR T2 maps correlate with the citrate concentration in the prostate. NMR Biomed. 1996; 9(2):59-64. DOI: 10.1002/(SICI)1099-1492(199604)9:2<59::AID-NBM400>3.0.CO;2-2. View

Heijmink S, Futterer J, Hambrock T, Takahashi S, Scheenen T, Huisman H . Prostate cancer: body-array versus endorectal coil MR imaging at 3 T--comparison of image quality, localization, and staging performance. Radiology. 2007; 244(1):184-95. DOI: 10.1148/radiol.2441060425. View

Chan I, Wells 3rd W, Mulkern R, Haker S, Zhang J, Zou K . Detection of prostate cancer by integration of line-scan diffusion, T2-mapping and T2-weighted magnetic resonance imaging; a multichannel statistical classifier. Med Phys. 2003; 30(9):2390-8. DOI: 10.1118/1.1593633. View

Kjaer L, Thomsen C, Iversen P, Henriksen O . In vivo estimation of relaxation processes in benign hyperplasia and carcinoma of the prostate gland by magnetic resonance imaging. Magn Reson Imaging. 1987; 5(1):23-30. DOI: 10.1016/0730-725x(87)90480-2. View

Liney G, Knowles A, Manton D, Turnbull L, Blackband S, Horsman A . Comparison of conventional single echo and multi-echo sequences with a fast spin-echo sequence for quantitative T2 mapping: application to the prostate. J Magn Reson Imaging. 1996; 6(4):603-7. DOI: 10.1002/jmri.1880060408. View

Gibbs P, Liney G, Pickles M, Zelhof B, Rodrigues G, Turnbull L . Correlation of ADC and T2 measurements with cell density in prostate cancer at 3.0 Tesla. Invest Radiol. 2009; 44(9):572-6. DOI: 10.1097/RLI.0b013e3181b4c10e. View

Xu S, Kruecker J, Turkbey B, Glossop N, Singh A, Choyke P . Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies. Comput Aided Surg. 2008; 13(5):255-64. PMC: 2664902. DOI: 10.3109/10929080802364645. View

10.

Gibbs P, Tozer D, Liney G, Turnbull L . Comparison of quantitative T2 mapping and diffusion-weighted imaging in the normal and pathologic prostate. Magn Reson Med. 2001; 46(6):1054-8. DOI: 10.1002/mrm.1298. View

11.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

12.

Langer D, van der Kwast T, Evans A, Trachtenberg J, Wilson B, Haider M . Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging. 2009; 30(2):327-34. DOI: 10.1002/jmri.21824. View

13.

Turkbey B, Pinto P, Mani H, Bernardo M, Pang Y, McKinney Y . Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation. Radiology. 2010; 255(1):89-99. PMC: 2843833. DOI: 10.1148/radiol.09090475. View

14.

Roebuck J, Haker S, Mitsouras D, Rybicki F, Tempany C, Mulkern R . Carr-Purcell-Meiboom-Gill imaging of prostate cancer: quantitative T2 values for cancer discrimination. Magn Reson Imaging. 2008; 27(4):497-502. PMC: 2720831. DOI: 10.1016/j.mri.2008.08.001. View

15.

Liney G, Turnbull L, Lowry M, Turnbull L, Knowles A, Horsman A . In vivo quantification of citrate concentration and water T2 relaxation time of the pathologic prostate gland using 1H MRS and MRI. Magn Reson Imaging. 1997; 15(10):1177-86. DOI: 10.1016/s0730-725x(97)00182-3. View

16.

Turkbey B, Albert P, Kurdziel K, Choyke P . Imaging localized prostate cancer: current approaches and new developments. AJR Am J Roentgenol. 2009; 192(6):1471-80. PMC: 3523175. DOI: 10.2214/AJR.09.2527. View

17.

Turkbey B, Pinto P, Choyke P . Imaging techniques for prostate cancer: implications for focal therapy. Nat Rev Urol. 2009; 6(4):191-203. PMC: 3520096. DOI: 10.1038/nrurol.2009.27. View

18.

Senegas J, Liu W, Dahnke H, Song H, Jordan E, Frank J . Fast T(2) relaxometry with an accelerated multi-echo spin-echo sequence. NMR Biomed. 2010; 23(8):958-67. DOI: 10.1002/nbm.1521. View

19.

Singh A, Kruecker J, Xu S, Glossop N, Guion P, Ullman K . Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy. BJU Int. 2007; 101(7):841-5. PMC: 2621260. DOI: 10.1111/j.1464-410X.2007.07348.x. View